NCT05565248View on ClinicalTrials.gov

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 20, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

August 31, 2025

Conditions
Diabetes MellitusDiabetes Mellitus, Type 1Glucose Metabolism DisordersMetabolic DiseaseEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases
Interventions
COMBINATION_PRODUCT

VCTX211

CRISPR-Cas9 genetically modified PEC211 cells loaded into a delivery device

Trial Locations (2)

Unknown

RECRUITING

University of Alberta, Edmonton

RECRUITING

University of British Columbia, Vancouver

Sponsors

Collaborators (1)

ViaCyte
All Listed Sponsors
collaborator

ViaCyte

INDUSTRY

lead

CRISPR Therapeutics AG

INDUSTRY

NCT05565248 - An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D | Biotech Hunter | Biotech Hunter